Lumida
/WVE
⌘K
WAVE Life Sciences Ltd

WAVE Life Sciences Ltd

WVE
$4.59USD-1.71%-0.08 today

MARKET CAP

904.5M

P/E (TTM)

FWD P/E

DAY RANGE

$5 – $5

52W RANGE

$5
$22

AI Summary

Stalk
TrimMedium

In a Stage 4 decline, WVE remains under sustained seller control with price below all key EMAs and forming sequential lower highs and lower lows. Despite extreme oversold readings and a bearish exhaustion signal, no stable base has formed, and rallies continue to stall on muted volume. The medium-term bias is bearish, and sellers should defer new execution until rallies into resistance rather than selling into diminishing downside momentum.

  • WVE-007 achieved placebo-adjusted 4% total fat and 9.2% visceral reduction at 240 mg dose over three months.
  • Proprietary RNAi/editing technology targets inhibin E, preserving lean mass versus GLP-1 therapies.
  • Q2 2026 net loss rose to $69.4 M from $50.5 M YoY, with R&D up to $51.3 M.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$41.0M$3.6M$113.3M$108.3M$42.7M
YoY %+104.0%-91.1%+3005.1%-4.4%-60.5%
P / Sales4.0x134.0x5.0x15.8x67.1x
EV / Sales4.4x160.0x5.2x14.2x55.6x
Gross Profit, Adj.$41.0M$3.6M$113.3M$108.3M$42.7M
YoY %+104.0%-91.1%+3005.1%-4.4%-60.5%
Margin %100.0%100.0%100.0%100.0%100.0%
EV / Gross Profit4.4x160.0x5.2x14.2x55.6x
EBITDA, Adj.$-119.5M$-156.1M$-63.0M$-106.5M$-211.9M
YoY %+16.6%-30.6%+59.7%-69.1%-99.0%
Margin %-291.8%-4279.1%-55.6%-98.3%-496.0%
EV / EBITDA-1.5x-3.7x-9.4x-14.5x-11.2x
EBIT$-127.0M$-162.7M$-68.0M$-110.4M$-215.4M
YoY %+17.2%-28.1%+58.2%-62.4%-95.1%
Margin %-310.1%-4459.3%-60.0%-101.9%-504.1%
EV / EBIT-1.4x-3.6x-8.7x-14.0x-11.0x
Net Income$-122.2M$-161.8M$-57.5M$-97.0M$-204.4M
YoY %+18.5%-32.4%+64.5%-68.7%-110.7%
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (GAAP)-$2.36-$2.05-$0.54-$0.70-$1.21
YoY %+38.2%+13.1%+73.7%-29.6%-72.9%